This is a demo store. No orders will be fulfilled.
USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Life Sciences
Frost & Sullivan's expertise in Life Sciences research and consulting includes work in diversified strategic and operational areas
The life sciences industry is undergoing rapid change, dynamic discoveries and pressures driving business decisions and corporate growth. Business models are being forced to evolve as healthcare continues to shift from a treatment focus to points of wellness, prediction, personalization, and prevention.
Recognizing the interdependence of the payer, provider and pharmaceutical value chains, companies are re-inventing strategies in multitude ways: increased outsourcing, co-development and patient engagement are the new norms.
The Frost & Sullivan Global Life Sciences Program helps you better understand stakeholder dynamics as the healthcare system transitions from acute care into integrated care. Our research and insights help you make informed strategic decisions around how best to navigate this complex market.
We can support needs from syndicated research to projects ranging from proprietary strategic engagements and market research, marketing solutions, and whitepapers, all leveraging the global reach of our firm to propel your business forward.
We believe a structured partnership that provides you transformational insights through online content as well as deeper interaction with our senior analyst team will help ensure greater relevancy of insights provided for your organization.
-
30 Mar 2016 | Global | Technology Research
Diagnostic Breakthroughs for Neurodegenerative Diseases
R&D on Overdrive to Address Intensifying Disease Burden, Neuroimaging Technologies to Remain Gold-standard for Neurodiagnostic Applications
This research service covers key technological trends and developments in diagnostics for neurodegenerative diseases, which are likely to have a high impact in the near future. The technologies present across the global neurodiagnostic industry have been covered under neurobiomarkers, neuroimaging and neuroinformatics segments. While providing brie...
$4,950.00 -
29 Mar 2016 | Global | Market Research
Top 50 Emerging Technologies: Growth Opportunities of Strategic Imperative
Multi-billion dollar technologies ready to propel industries and transform our world
Research Overview The Top 50 Emerging Technologies research is a comprehensive analysis of the most promising and disruptive technologies poised to impact our world in the next few years. It highlights and offers strategic guidance and actionable ideas on the hottest 50 technologies that pack maximum potential to fuel global innovation; spawn in...
$7,500.00 -
18 Mar 2016 | North America | Market Research
Vital Signs - Stem Cell Therapy in Ischemic Stroke Recovery
Additional Clinical Trials Critical to Building on Early Promise
As indicated by the World Health Organization, stroke is the second-leading cause of death for people over the age of 60 and is the fifth-leading cause of death for those between the ages of 15 and 59. The incidence of stroke is expected to increase by 25% over the next 20 years. Over 40% of ischemic stroke victims have permanent symptoms and only ...
$450.00 -
18 Mar 2016 | North America | Market Research
Vital Signs - Drug Development Focus on Genetically Modified Swine
Modified Swine Hold out Promise of Improving Pre-Clinical Efficacy, Lowering Multi-billion Dollar Drug and Device Development Costs
The US pharmaceutical industry spends approximately $100 billion annually to develop new pharmaceutical drugs and medical devices. Today, a new drug takes approximately 15 years and over $1 billion to bring to market. Product development costs could be greatly reduced by using animal models that more closely resemble humans in their disease states ...
$450.00 -
05 Jan 2016 | Global | Market Research
Vital Signs - Advances in Cancer Treatment, Clampdown on Specialty Pharmacies and Strategy Revamp for Sequencing Provider, An Analysis
Liquid Biopsy Test for Prostate Cancer and Non-small Cell Lung Cancer Treatment Show Promise
This issue of Vital Signs discusses MDxHealth's launch of the SelectMDx Liquid Biopsy Test in Europe, the FDA's approval of a new treatment for non-small cell lung cancer with EGFR mutations, the clamp down on specialty pharmacies by US drug benefit managers, and BGI's strategy redirection for Complete Genomics.
$450.00
